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Health economics and outcomes research 
(HEOR) is becoming increasingly important as 
governments and healthcare organizations deal with 
the problem of providing the best possible health 
outcomes at an affordable cost. The International 
Society for Pharmacoeconomics and outcomes 
research (ISPOR) is a leading professional society in 
this field. Recently a survey was conducted among 
ISPOR members who are experts in the fields 
regarding the top ten trends in HEOR predicted to 
have the maximum impact during 2018. 
The top trends have recently been highlighted 
in a booklet published by ISPOR. The top ten trends 
identified are drug pricing and spending, innovative 
and curative therapies, accelerated drug approvals, 
universal health coverage, aging population, 
mHealth, diagnostics, biosimilars, preventive 
medicine, and disruptive innovators. 
Drug prices constitute a large proportion of 
the healthcare budget. Indication-specific pricing 
is being increasingly recommended especially 
when drugs have both a high-value and a low-value 
indication. Specialty drugs are being developed more 
rapidly and while these are effective for a variety of 
conditions their high cost will put pressure on health 
systems. 
Innovative and curative therapy is a 
transformational change to the health sector but 
it brings a high economic burden. In developing 
countries like Nepal, their high cost could put them 
beyond the reach of the majority of the population 
unless ‘creative’ drug financing mechanisms are put 
in place. 
Accelerated drug approval mechanism has 
been initiated in many countries but the benefits 
have to be balanced against the risks especially in 
terms of patient safety and the initial pricing and 
reimbursement. 
Universal health coverage is becoming 
increasingly common around the world. The first 
steps were taken in Europe following the Second 
World War but today most developing countries 
including Nepal are working towards this. 
The aging world population creates unique 
challenges and the issue for health systems and 
countries is balancing cost and quality of care. 
A number of applications on smart phones 
or devices which can connect to smart phones can 
continuously monitor individuals’ vital parameters 
and generate an enormous amount of real-time data. 
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The challenge is learning to make better use of this 
data and to evaluate real-world evidence. 
 Diagnostics plays an important role in 
deciding which patients can benefit the most from 
advanced therapeutic modalities. HEOR will play an 
important role regarding decisions about the use and 
reimbursement of diagnostics. 
 A biosimilar has been defined as a biological 
medical product which is almost identical copy of 
an original product which has been manufactured 
by a different company. Biosimilars thus share 
similarities with generic medicines and while the 
cost saving may be lower compared to generics they 
still have the potential to save  billions of dollars. 
 Chronic diseases are becoming common 
and a large proportion of the burden is borne by 
developing countries. Evaluating risk levels and 
targeting interventions appropriately can ensure 
cost-effective prevention. 
 The last trend is the development of 
disruptive technologies. These can range from 
gene editing using Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR), to Chimeric 
Antigen Receptors (CAR) T-cell therapies among 
others. Multiple criteria decision analysis in groups 
is recommended to make decisions regarding use of 
these technologies. This is similar to the personal 
drug selection process taught in schools around the 
world. 
 The booklet ends with references, a 
description of the process of developing the 
booklet and the individuals involved. This small 
but highly informative booklet will be of interest 
to all individuals interested in HEOR and is vitally 
important for a developing country like Nepal with 
resource constraints.
 ISPOR 2018 Top 10 HEOR trends can be 
downloaded for free from https://www.ispor.org/
top10trends.pdf
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